Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918476 | 0.82 | ADORA1 (0.54) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL4362864 | 0.81 | ADORA1 (0.41) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL3199658 | 0.79 | ADORA1 (0.40) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL6494388 | 0.78 | HTT (0.43) | HTTADORA3SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL31218454 | 0.78 | HTT (0.43) | HTTADORA3SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL4368747 | 0.76 | HTT (0.45) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL3211435 | 0.76 | ADORA1 (0.37) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL3206001 | 0.74 | NOS3 (0.38) | HTTGAAADORA1ADORA3ADORA2A | |
| SCHEMBL3218809 | 0.74 | POLB (0.41) | GAASMN1; SMN2DDAH1L3MBTL1TP53 | |
| SCHEMBL3210413 | 0.73 | ADORA1 (0.36) | HTTGAAADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2125806-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | Pfizer Products Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | HTT 3537/4885GAA 482/4885ADORA1 1622/4885 |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | HTT 2265/4885GAA 3391/4885ADORA1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.